Project profile — Affordable Medicine Facility for Malaria

• Cambodia (0.22%)
• Tanzania (11.42%)
• Uganda (14.96%)
• Kenya (15.35%)
• Madagascar (0.94%)
• Niger (1.54%)
• Nigeria (39.69%)
• Ghana (15.88%)

• Basic Health: Malaria control (12262) (100.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (principal objective)
• Participatory development and good governance (significant objective)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (principal objective)
• Youth Issues (principal objective)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (principal objective)

The Affordable Medicine Facility for malaria (AMFm) is a pilot financing mechanism designed to make ACTs (artemisinin-based combination therapies) more affordable and accessible for those who need them most. ACTs are the most effective treatment for malaria and, by making them more affordable, the AMFm also aims to reduce the use of less effective treatments. To reduce the cost of ACT treatments for patients, the AMFm negotiates with drug manufacturers to reduce the price of ACTs and also provides a subsidy to buyers. The AMFm also provides funding to recipient countries to support activites that promote safe and proper use of ACTs. These activities include training, supervision, and marketing and information campaigns. They also include special efforts to reach more vulnerable populations, to ensure that they are more aware of the effectiveness of ACTs. CIDA's contribution to the AMFm helps to meet increasing demands for funding, due to the encouraging results of the first phase of the pilot.

N/A

N/A

• Proactive disclosure
• Related activities: Affordable Medicines Facility for Malaria - 2012-2013